Mead Johnson & Company

Bristol-myers Squibb Compnay

Bristol-myers Company

Claude E Gallian

Stephen T David

Robert J Bequette

John R Reckelhoff

Bruce A Bonenberger

Dana Brooke

Michael K Ullman

Charles Williams

Joseph C Chou

Gepirone compositions having extended release properties contain a gepirone salt, a cellulosic polymer matrix and suitable quantities of pharmaceutical excipients. Dosage forms based thereon require 18 to 24 hours for release of 90 to 95% of gepirone.

Gepirone dosage form

A directly compressed cholestyramine tablet with a solvent-free coating is disclosed. The inner core of the tablet is made up of cholestyramine agglomerates consisting of numerous small, irregularly-shaped, jagged-edged fragments having relatively few smooth or flat surfaces with a moisture content ranging from about 8 to 14 percent by weight. A process is also disclosed for preparing cholestyramine agglomerates of the invention. The solvent-free coating comprises from about 60 percent to about 95 percent by weight of stearic acid and from about 5 percent to about 40 percent of polyethylene glycol.

Direct compression cholestyramine tablet and solvent-free coating

Direct compression cholestyramine tablet and solvent-free coating thereof

A directly compressible pharmaceutical composition comprising cyclophosphamide and a partially or fully pregelatinized starch is disclosed. The pharmaceutical composition, when directly compressed into a tablet, exhibits unexpected stability when compared to cyclophosphamide in combination with other direct compression vehicles.

Direct compression cyclophosphamide tablet

Non-disintegrating theophylline tablets having a pair of opposing substantially planar surfaces and a very thin cross-section have a high bioavailability on ingestion and a relatively steady release rate permitting a 12 hr. dosing interval for maintenance of non-toxic therapeutic blood theophylline concentrations. Excipients or tableting aids are not required, but trace amounts of a tableting lubricant are preferably included to facilitate continuous large scale production.

Sustained release tablet containing at least 95 percent theophylline

The invention disclosed provides a multi-fractionable tablet structure initially configurated in a unitary dosage while having readily severable sub-dosage units as components thereof. Score markings are positioned variously about the tablet such as along the top and bottom surfaces thereof. Additionally, score markings may appear along opposite vertical side surfaces of the tablet. Special placement of the score markings readily permits alternatively an accurate equal bisectional or trisectional fracture of the tablet as may be desired for patient consumption.

Multi-fractionable tablet structure

The invention disclosed provides a multi-fractionable tablet structure initially configurated in a unitary dosage while having readily severable sub-dosage units as components thereof. Score markings are positioned variously about the tablet both along the top and bottom surfaces of an approximately rectangular configuration whereas in preferred embodiments thereof, score markings additionally appear along opposite vertical side surfaces of the tablet. Special placement of the score markings readily permit at least either an accurate bisectional fracture or accurate trisectional fracture of the tablet as may be desired for patient consumption.

A tablet for controlled release of a water soluble medicament or dietary supplement is comprised of a water insoluble wax-like matrix core containing the water soluble medicament and coated with a permeable erosion resistant polymeric film. The core constitutes 95% or more of the tablet weight.

Growing community of inventors

Newburgh, IN, United States of America

Claude E Gallian